Rep. Kevin Hern (R-OK) Sells IQVIA (IQV) Stock
Oklahoma Congressman Kevin Hern sold shares of IQVIA Holdings valued between $1,001 and $15,000.
Reviewed by automated data checks against the source filing. How we make and check alerts
Rep. Kevin Hern (R-OK) sold between $1,001 and $15,000 of IQVIA Holdings Inc. ($IQV) stock on September 3, 2026. The trade was disclosed in a STOCK Act periodic transaction report filed September 25, 2026.
Since the trade, $IQV is down 5.3% after 1 week, down 2.0% after 1 month and down 1.7% to date (from the $271.62 close on Sep 3, 2026).
Financial Disclosure Report
Clerk of the House of Representatives • Legislative Resource Center • B81 Cannon Building • Washington, DC 20515
Filer Information
- Name:
- Rep. Kevin Hern (R-OK)
- Status:
- Member — House
- State/District:
- OK-1
- Party:
- Republican
Filing Information
- Filing Type:
- Periodic Transaction Report
- Filing Year:
- 2026
- Filing Date:
- Sep 25, 2026
Schedule B: Transactions
| Asset | Transaction | Date | Amount |
|---|---|---|---|
| IQVIA Holdings Inc. ($IQV) | Sell | Sep 3, 2026 | $1,001 - $15,000 |
Summary of the filed report, not the original document. Find the original: House financial disclosure search
IQV
IQVIA Holdings Inc.
Key Points
- Kevin Hern sold shares of IQVIA Holdings valued between $1,001 and $15,000 on September 3, 2026, as reported on September 25.
- The stock is currently trading at $270.45, close to its 52-week high of $273.88, reflecting strong market performance.
- IQVIA has a strong buy consensus among analysts, with price targets reaching as high as $329.
Get $IQV trade alerts by text
We text you when insiders, Congress or big funds trade $IQV. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated IQVIA Holdings Inc. alert may contain errors. Disclosures
Oklahoma Congressman Kevin Hern sold shares of IQVIA Holdings Inc. (IQV) on September 3, 2026. The sale was valued between $1,001 and $15,000 and reported on September 25. Hern is a Republican member of the House, representing Oklahoma's 1st District.
Kevin Hern vs. the S&P 500
Hypothetical returns from Kevin Hern's disclosed trades, not real profit or advice. How we model this.
Inside Kevin Hern's Trade
Hern's reported transaction involved selling shares of IQVIA, a leading provider of clinical research and healthcare intelligence services. The transaction occurred at a time when the stock was trading at $270.45, nearing its 52-week high of $273.88.
Other Institutional Activity in IQVIA Holdings
Several major funds have adjusted their positions in IQVIA Holdings. BlackRock Inc. reduced its stake by 477,877 shares, ending up with 14,549,693 shares valued at about $3.85 billion. Vanguard Capital Management LLC also trimmed its holdings, decreasing by 122,405 shares to 10,905,053 shares, worth approximately $2.88 billion. Meanwhile, State Street Corporation increased its position slightly, adding 31,403 shares for a total of 7,508,244 shares valued at around $1.98 billion.
IQVIA Holdings Inc. Stock Up 1.5%
As of the article's publication, IQV shares were priced at $270.45, which shows strong momentum as it trades near its 52-week peak. The company has seen a solid recovery after dipping to a low of $154.50 over the past year, underscoring positive investor sentiment.
Recent Earnings
In its latest quarter, IQVIA reported revenue of approximately $16.98 billion, reflecting an 8.7% growth compared to the previous year. Its earnings per share were $8.05, with a net margin of 8.1%. The next earnings report is expected on November 3, 2026.
Analysts Set New Price Targets
On September 29, 2026, RBC Capital maintained an "Outperform" rating with a price target of $319. Truist Securities reiterated a "Buy" rating with a target of $329 on September 28. Other firms, including Stifel and Mizuho, have also kept their ratings at "Buy" and "Outperform" with targets of $303 and $300, respectively.
About IQVIA Holdings Inc.
IQVIA Holdings provides essential services for clinical research and healthcare insights across the globe. The company operates in several segments, including Technology & Analytics Solutions and Research & Development Solutions, catering to life sciences and healthcare sectors. In a robust healthcare market, its performance remains strong, highlighted by a solid analyst consensus.
Bottom Line
Investors should keep an eye on IQVIA's upcoming earnings release on November 3, 2026, for further insights into its performance. The recent trading activity, including Hern's share sale, reflects broader market trends. Keep in mind that this sale was reported following his previous transactions in September involving other companies.
Related Filing Alerts
Source: Kevin Hern's STOCK Act disclosure on $IQV (Sep 3, 2026). Find the original filing: House financial disclosure search. Written by software, not financial advice. How we make alerts